Facebook
Twitter
LinkedIn
ForwardUpdate on Therapeutics in Inborn Errors
The Update on Therapeutics in Inborn Errors session will discuss updates and discussion of novel therapies including gene therapy trials and techniques.
Commercial Supporter
This educational activity is supported by an educational grant from Ultragenyx.
Learning Objectives
- Better understand the driver’s of therapeutic development on inborn errors of metabolism
- Appreciate the role of the Orphan Drug Act on rare disease treatments
- Recognize ways to be involved in drug development for rare IEMs
Medical Biochemical Genetics is hosted virtually via Zoom. Zoom details will be provided after registering for the course.
Guest Faculty
Shawn McCandless, MD
Children's Hospital Colorado
Disclosures
Shawn McCandless, MD, speaker for this activity, is a consultant for Levo Therapeutics, a speaker for Horizon Therapeutics and a researcher for Aardvark Therapeutics, Ultragenyx and Harmony Therapeutics.
Planners, faculty, and others in control of content (either individually or as a group) have no relevant financial relationships with ineligible companies.
All of the relevant financial relationships listed have been mitigated.
Medical
Children’s Hospital Colorado is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Children’s Hospital Colorado designates this Live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Others
A general certificate of attendance will be available after the completion of the online evaluation. Claim only credit commensurate of your conference attendance.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Attendance